 |
|
|
|
|
|
Treatment |
|
Location |
|
Last Updated |
|
|
|
Details |
|
The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Durham, NC USA |
|
11/24/2008 |
|
|
|
|
|
Details |
|
The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New York, NY USA |
|
11/24/2008 |
|
|
|
Details |
|
The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Tampa, FL USA |
|
11/24/2008 |
|
|
|
|
|
Details |
|
The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Los Angeles, CA USA |
|
11/24/2008 |
|
|
|
Details |
|
The GLASS-ART Trial: A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Omaha, NE USA |
|
11/24/2008 |
|
|
|
|
|
Details |
|
Phase II/III randomized study of CDX-110 with radiation and temozolomide in patients with newly diagnosed glioblastoma |
|
Houston, TX USA |
|
10/27/2008 |
|
|
|
Details |
|
A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme
|
|
Houston, TX USA |
|
10/27/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Chicago, IL USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Detroit, MI USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Durham, NC USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Charlottesville, VA USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Cleveland, OH USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Cleveland, OH USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Hackensack, NJ USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Syracuse, NY USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Chicago, IL USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Los Angeles, CA USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Boston, MA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New Haven, CT USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Buffalo, NY USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Salt Lake City, UT USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Columbus, OH USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Evanston, IL USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Palo Alto, CA USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New York, NY USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Houston, TX USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Seattle, WA USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New York, NY USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Jacksonville, FL USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
San Francisco, CA USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Saginaw, MI USA |
|
10/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Gainsville, FL USA |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
San Antonio, TX USA |
|
10/09/2008 |
|
|
|
Details |
|
Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and CMV Infection |
|
Umea, Sweden |
|
10/09/2008 |
|
|
|
|
|
Details |
|
Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and CMV Infection |
|
Uppsala, Sweden |
|
10/09/2008 |
|
|
|
Details |
|
Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients With Malignant Glioblastoma and CMV Infection |
|
Solna, Stockholm, Sweden |
|
10/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme |
|
San Francisco, CA USA |
|
07/23/2008 |
|
|
|
Details |
|
Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer |
|
Cincinnati, Oh USA |
|
06/04/2008 |
|
|
|
|
|
Details |
|
Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients with Recurrent Malignant Glioma
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase 2, 2-part, multicenter, open-label study to evaluate the safety, tolerability, and efficacy of CT-322 (Angiocept™) monotherapy and combination therapy with irinotecan in patients with recurrent glioblastoma multiforme
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
San Antonio, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Madison, WI USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Pittsburgh, PA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Boston, MA USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Boston, MA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Study of GP96 Heat Shock Protein-Peptide Complex Vaccine in Patients With Recurrent or Progressive High-Grade Glioma |
|
San Francisco, CA USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
A phase I/II Evaluation of Vaccination with Type-1 Dendritic Cells Pulsed With Multiple Peptides In the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas |
|
Pittsburgh, PA USA |
|
03/02/2008 |
|
|
|
Details |
|
Chemotherapy, Radiation Therapy, and Vaccine Therapy With or Without Daclizumab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery |
|
Durham, NC USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
Details |
|
A Phase l Trial of Tumor Associated Antigen Pulsed Dendritic Cell Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
Details |
|
Phase I Study of Glioma-Associated Antigen (GAA) Peptide-Pulsed Dendritic Cell Vaccination in Malignant Glioma Patients |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
A Phase l Trial of Surgical Resection With Gliadel Wafer Placement Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate for Patients With Malignant Glioma
|
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
Details |
|
Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-Specific T-Cell Adoptive Transfer [ERaDICATe] |
|
Durham, NC USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
Phase I Study of Immunization With Autologous Tumor Lysate-Pulsed Dendritic Cells in Patients With Malignant Gliomas (Vaccine Therapy in Treating Patients With Malignant Glioma) |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
Details |
|
Phase I/II trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine For Patients With Recurrent High Grade Glioma |
|
San Francisco, CA USA |
|
10/03/2007 |
|
|
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
New York, NY USA |
|
08/26/2007 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Cincinnati,, OH USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Columbus, OH USA |
|
08/26/2007 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Toronto, Ontario, CANADA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Phase I/II Study of ATN-161 and Carboplatin in Adult Patients With Recurrent Intracranial Malignant Glioma |
|
Bethesda, MD USA |
|
08/26/2007 |
|
|
|
Details |
|
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas |
|
Bethesda, MD USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
08/26/2007 |
|
|
|
Details |
|
Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme |
|
Charleston, SC USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
Open-Label Dose Confirmation and Dosimetry Study of Interstitial 131I-chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
08/26/2007 |
|
|
|
Details |
|
Determination of the In-Tumor-Concentration of Imatinib Mesylate (Gleevec) in Malignant Glioma After Oral Administration |
|
Baltimore, MD USA |
|
08/20/2007 |
|
|
|
|
|
Details |
|
Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms |
|
New York, NY USA |
|
08/20/2007 |
|
|
|
Details |
|
A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas |
|
Vista, CA USA |
|
08/20/2007 |
|
|
|
|
|
Details |
|
Eligibility Screening Of Patients With Central Nervous System Tumors For The National Cancer Institute`s (NCI) Clinical Research Protocols |
|
Bethesda, MD USA |
|
08/20/2007 |
|
|
|
Details |
|
A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas |
|
Chicago, IL USA |
|
08/20/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial of Bevacizumab (Avastin) and Irinotecan (CPT-11) for Patients With Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment With Bevacizumab Alone |
|
Bethesda, MD USA |
|
08/19/2007 |
|
|
|
Details |
|
Phase II Trial of Intralesional Adoptive Cellular Therapy of Glioblastoma With Interleukin-2-Stimulated Lymphocytes |
|
Newport Beach, CA USA |
|
08/19/2007 |
|
|
|
|
|
Details |
|
Gliadel and Dendritic Cell Vaccine for Malignant Glioma |
|
Los Angeles, CA USA |
|
08/18/2007 |
|
|
|
Details |
|
A Phase II Trial of Dendritic Cell Vaccine Pulsed with Tumor Lysate Followed by Temozolomide Upon Recurrence in Patients with Newly Diagnosed Glioblastoma |
|
Los Angeles, CA USA |
|
08/18/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial With Bevacizumab (Avastin) and Irinotecan (CPT-11) for Patients With Primary Brain Tumors and Progression After Standard Therapy |
|
Copenhagen, Denmark |
|
08/18/2007 |
|
|
|
Details |
|
A Phase II Study of Bevacizumab (Avastin) in Combination With Metronomic Temozolomide (Temodar)for Recurrent Malignant Glioma |
|
Durham, NC USA |
|
08/18/2007 |
|
|
|
|
|
Details |
|
Phase II Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients with Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System |
|
Los Angeles, CA USA |
|
08/18/2007 |
|
|
|
Details |
|
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
|
Pittsburgh, PA USA |
|
08/04/2007 |
|
|
|
|
|
Details |
|
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
|
Houston, TX USA |
|
08/04/2007 |
|
|
|
Details |
|
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
|
Los Angeles, CA USA |
|
08/04/2007 |
|
|
|
|
|
Details |
|
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
|
Madison, WI USA |
|
08/04/2007 |
|
|
|
Details |
|
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
|
Boston, MA |
|
08/04/2007 |
|
|
|
|
|
Details |
|
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma |
|
New York, NY USA |
|
08/04/2007 |
|
|
|
Details |
|
Open-label, Dose Confirmation and Dosimetry Study of Interstitial 131-I chTNT-1/B mAb (Cotara®) for the Treatment of Recurrent Glioblastoma Multiforme (GBM) |
|
Tustin, CA USA |
|
07/31/2007 |
|
|
|
|
|
Details |
|
A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors |
|
Chicago, IL USA |
|
06/04/2007 |
|
|
|
Details |
|
A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors |
|
Birmingham, AL USA |
|
06/04/2007 |
|
|
|
|
|
Details |
|
A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors |
|
Cambridge, MA USA |
|
06/04/2007 |
|
|
|
Details |
|
A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors |
|
Grand Rapids, MI USA |
|
06/04/2007 |
|
|
|
|
|
Details |
|
A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labelled Chlorotoxin In Patients with Recurrent or Refractory Somatic and/or Cereberal Metastatic Solid Tumors |
|
Dallas, TX USA |
|
06/04/2007 |
|
|
|
Details |
|
Phase I and II, Open-Label, Multi-Center Trials of Pazopanib in Combination With Lapatinib in Adult Patients With Relapsed Malignant Glioma |
|
Tampa, FL USA |
|
05/01/2007 |
|
|
|
|
